ORPHA:79301
Congenital bile acid synthesis defect type 1
Also known as: 3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency · BASD1
Query health: suspect — Only one of 3 strategies returned hits (phrase).
Publications
22
35.6th percentile
Trials
0
Interventional, condition-specific
Researchers
111
Distinct authors in sample
Gene link
HSD3B7
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
bile acid synthesis defect type 1 (BAS defect type 1) is the most common anomaly of bile acid synthesis characterized by variable manifestations of cholestatic liver disease, and fat malabsorption.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011906
- MeSH:C535442
- OMIM:607765
- UMLS:C1843116
Additional Mondo synonyms (7)
3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency type 1 · CBAS1 · HSD3B7 congenital bile acid synthesis defect · bile acid synthesis defect, congenital, type 1 · congenital bile acid synthesis defect 1 · congenital bile acid synthesis defect caused by mutation in HSD3B7 · congenital bile acid synthesis defect type 1
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — HSD3B7
- LiteraturePresent
22 matched papers (18 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (HSD3B7).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
22
22 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
22 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
18 in the last 10 years · high confidence · 35.6th percentile (publications denominator)
Phrase hits: 22 · MeSH hits: 0
Who's working on it?
111
Distinct author names in 22 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Fang F2 papers · 2024
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Papers in Europe PMC - 02Giordano G2 papers · 2026
Mass Spectrometry Laboratory, Women's and Children's Health Department, University of Padua, Institute for Pediatric Research (IRP), Padua.
Papers in Europe PMC - 03Naturale M2 papers · 2026
Mass Spectrometry Laboratory, Women's and Children's Health Department, University of Padua, Institute for Pediatric Research (IRP), Padua.
Papers in Europe PMC - 04Zhou H2 papers · 2024
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 05Al-Jasmi FA1 paper · 2016
Department of Pediatrics, United Arab Emirates University, P.O. Box 17666, Al-Ain, UAE. aljasmif@uaeu.ac.ae.
Papers in Europe PMC - 06
- 07Anderson DK1 paper · 2011
University of Michigan, Ann Arbor, MI, USA. debcarl@umich.edu
Papers in Europe PMC - 08Baumann U1 paper · 2022
Division of Paediatric Gastroenterology and Hepatology, Department of Paediatric Liver, Kidney and Metabolic Diseases, Hannover Medical School, 30625 Hannover, Germany.
Papers in Europe PMC - 09Blair IA1 paper · 2024
Centers for Cancer Pharmacology and Excellence in Environmental Toxicology, Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania.
Papers in Europe PMC - 10Bossi G1 paper · 2017
Pediatric Department, IRCCS Foundation Policlinico San Matteo, Pavia.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category congenital bile acid synthesis defect also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: congenital bile acid synthesis defect
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Congenital bile acid synthesis defect type 1" OR "3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency" OR "BASD1" OR "3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency type 1" OR "CBAS1" OR "HSD3B7 congenital bile acid synthesis defect" OR "bile acid synthesis defect, congenital, type 1" OR "congenital bile acid synthesis defect 1" OR "congenital bile acid synthesis defect caused by mutation in HSD3B7"
MeSH descriptor terms unioned into the query: Bile acid synthesis defect, congenital, 1
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Congenital bile acid synthesis defect type 1" OR "3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency" OR "BASD1" OR "3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency type 1" OR "CBAS1" OR "HSD3B7 congenital bile acid synthesis defect" OR "bile acid synthesis defect, congenital, type 1" OR "congenital bile acid synthesis defect 1" OR "congenital bile acid synthesis defect caused by mutation in HSD3B7" OR "Bile acid synthesis defect, congenital, 1" OR "HSD3B7"
Recall-expansion terms: HSD3B7
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"congenital bile acid synthesis defect"
Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:14:04.959Z